On June 16, 2025 NanoCell Therapeutics, Inc. ("NanoCell"), a biotechnology company developing a non-viral, DNA-based in vivo gene therapy platform, reported the successful closing of a seed-extension financing round, with participation from The Institute for Follicular Lymphoma Innovation ("IFLI"), a leading non-profit organization dedicated exclusively to funding innovative follicular lymphoma research and development (Press release, NanoCell Therapeutics, JUN 16, 2025, View Source [SID1234653920]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The funding will accelerate IND-enabling development of NanoCell’s lead clinical candidate, NCTX-01, a dual-CAR CD19/CD22 in vivo CAR-T therapy for B cell malignancies. NanoCell will use the capital to further evaluate NCTX-01’s safety, efficacy and durability in treating aggressive forms of lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma.
"IFLI’s support enables us to accelerate NCTX-01 through preclinical development to clinical development," said Maurits Geerlings, MD, President & Chief Executive Officer of NanoCell. "This partnership provides crucial resources to generate the preclinical data package needed for regulatory discussions. IFLI shares our belief that non-viral in vivo approaches have transformative potential to address significant unmet medical needs for patients who currently have limited treatment options.
"NanoCell’s innovative platform offers a novel approach to treating both follicular lymphoma and diffuse large B-cell lymphoma and could potentially overcome many of the current barriers that limit patient access to CAR-T therapies," said Michel Azoulay, MD, MBA, Chief Medical Officer at IFLI. "Supporting this program aligns with IFLI’s mission to accelerate innovative therapies that can make a meaningful difference in the lives of patients."